Oxiperomide
Oxiperomide is an antipsychotic.[1] Clinical trials demonstrated that it can reduce dyskinesia in patients with Parkinson's disease who are taking dopamine agonists without increasing Parkinsonian symptoms. It does this by selectively antagonizing dopamine receptors.[2][3] Further development of this drug is not available. It appears to have never been marketed.
Clinical data | |
---|---|
Routes of administration | Oral |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C20H23N3O2 |
Molar mass | 337.423 g·mol−1 |
3D model (JSmol) | |
| |
|
See also
References
- Elks J (1990). "Oxiperomide". The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Dordrecht: Springer. ISBN 978-1-4757-2085-3.
- Bédard P, Parkes JD, Marsden CD (April 1978). "Effect of new dopamine-blocking agent (oxiperomide) on drug-induced dyskinesias in Parkinson's disease and spontaneous dyskinesias". British Medical Journal. 1 (6118): 954–956. doi:10.1136/bmj.1.6118.954. PMC 1603806. PMID 638546.
- Casey DE, Gerlach J (March 1980). "Oxiperomide in tardive dyskinesia". Journal of Neurology, Neurosurgery, and Psychiatry. 43 (3): 264–267. doi:10.1136/jnnp.43.3.264. PMC 490519. PMID 7373324.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.